Navigation Links
Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call
Date:10/21/2009

mpany's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory or related pharmaceutical products or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales force, which is focused on the respiratory and related markets; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein, other than statements of historical fact, including statements regarding the progress and timing of our product development programs and related trials, our strategy and our future operations and opportunities, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the results of preclinical studies and clinical trials with respect to our products under development, our ability to satisfy FDA and other regulatory requirements and the other factors described in Item 1A (Risk Factors) of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on March 26, 2009 and in our subsequent filings with the SEC. In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release, should not be relied upon as representing our views as of any other date and do not reflect the potential impact of any acquisitions, mergers, dispositions, business development transactio
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic Factive(R)
2. Cornerstone Therapeutics Announces Closing of Chiesi Transaction
3. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
4. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
5. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
6. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
7. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
8. Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming
9. Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch
10. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
11. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains ... these latent viruses is the Epstein Barr Virus (EBV), and ... (RA) is a chronic inflammatory disease that destroys the body’s ... RA patients have high concentrations of EBV DNA in their ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... ALTO, Calif., Dec. 2 Intradigm Corporation, a ... today,announced the issuance of United States patent 7,459,547, ... Silencing." The issued,patent, which is based on ... Stone Cook Chair of Biomedical Sciences and Professor ...
... 2 Cardiogenesis Corporation (Pink Sheets: CGCP), a leading developer ... from severe angina, today announced the addition of veteran medical ... Cohen as a member of the Company,s Board of Directors, ... , Mr. Cohen, 49, has over ...
... ENDO ), an innovative medical device ... used by urologists and,interventional radiologists for tissue and ... institutions including Mayo Clinic,Memorial Sloan-Kettering Cancer Center and ... among others, will present a total of 38 ...
Cached Biology Technology:Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics 2Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics 3Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors 2Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors 338 Cryoablation Studies, Exhibits Presented at National Radiological Society Meeting 238 Cryoablation Studies, Exhibits Presented at National Radiological Society Meeting 338 Cryoablation Studies, Exhibits Presented at National Radiological Society Meeting 4
(Date:4/24/2014)... RICHLAND, Wash. A common plant puts out a welcome ... the mat,s molecular mix. , The study published this week ... reveals new targets during the battle between microbe and ... team showed that the humble and oft-studied plant Arabidopsis ... from a pathogen. It,s as if a hostile army were ...
(Date:4/23/2014)... may contribute to early fetal death according to a ... of Children,s Hospital Los Angeles and Ulaanbaatar, Mongolia ... a paper published today in the journal BMC ... correlations" between seasonal ambient air pollutants and pregnancy loss ... of the highest levels of air pollution of all ...
(Date:4/23/2014)... disease, most in their mid-thirties and forties, face ... decline within two decades. "Mutant" protein clusters, long ... have been the primary focus of therapies in ... research from Prof. Gerardo Lederkremer and Dr. Julia ... Research and Immunology, in collaboration with Prof. Ulrich ...
Breaking Biology News(10 mins):How a plant beckons the bacteria that will do it harm 2How a plant beckons the bacteria that will do it harm 3Pollutants from coal-burning stoves strongly associated with miscarriages in Mongolia 2On the defensive 2On the defensive 3
... insight into genetic basis of human diseaseHigh-throughput sequencing of ... which can give clues to the genetic underpinning of ... information from the individual's two chromosomes. Yet many ... individuals' DNA at the level of each chromosome -- ...
... Prehistoric big game hunters and not the last ice age ... sloths and other North American great mammals such as mammoths, ... , Determining whether the first arrival of humans or the ... last Ice Age was responsible for the demise of prehistoric ...
... The National Programme on Substance Abuse Deaths (np-SAD) based at ... London, has found that there has been a decline in ... to 1,372 in 2004, a drop of eight per cent. ... for the year 2004 reported by Coroners and Procurators Fiscal ...
Cached Biology News:California computer scientists double volume of data in NIH biotech repository 2California computer scientists double volume of data in NIH biotech repository 3California computer scientists double volume of data in NIH biotech repository 4Study shows big game hunters, not climate change, killed off sloths 2Study shows big game hunters, not climate change, killed off sloths 3Continued reduction in the number of drug-related deaths in the UK 2Continued reduction in the number of drug-related deaths in the UK 3
... Start up kit. Includes configured Laptop PC ... 2 MultiBlock satellite thermal cyclers (non-robotic). ... User friendly software. Store/track run data. ... lid. Outstanding uniformity. Advanced control ...
Glycerokinase; from Bacillus stearothermophilus...
A compact, high-speed single tube reader unit designed for benchtop 2D barcode reading. The unit can be used with all of ABgene's 2D barcoded tubes, including the 2ml CryoCode tube....
... Ascent FL is equipped ... luminometric measurement technologies that ... of advanced features of ... Ascent. Fluoroskan Ascent FL ...
Biology Products: